Use access key #2 to skip to page content.
$67.20 0.31 (0.46%)
10/7/2008 10:46 AM

ImClone Systems, Inc. (IMCL)

CAPS Rating:
**

A biopharmaceutical company which advances oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.

View All Commentary (IMCL)

Recs

0

Avatar rye1102 (76.74) Submitted: 2/21/07 12:26 PM : Outperform Start Price: $29.32 IMCL Score: 156.21

Current price is near the average purchase price of Icahn. Pipeline has good potential. Interim CEO previously negotiated sale of company Guidant to BSX. Distinct possibility of sale of company...especially with Icahn involved.

Report this Post Replies: 0 | Reply

Featured Broker Partners